145 results
Page 3 of 8
8-K
EX-99.1
f4030l0w7tvj
9 Nov 20
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC
5:11pm
8-K
EX-99.1
clp46fg0t54lnm8 ob
5 Nov 20
Adaptimmune Reports Q3 Financial Results and Business Update
7:40am
8-K
EX-99.1
o1xwfvv0hc667g4r rrh
15 Oct 20
Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial
4:47pm
8-K
EX-99.1
wrncue7ptskr
28 Aug 20
Regulation FD Disclosure
10:44am
S-3ASR
ssclwtab
10 Aug 20
Automatic shelf registration
5:01pm
424B5
80mt982mm7p91yum7em
2 Jun 20
Prospectus supplement for primary offering
5:05pm
424B5
o1uo 52vfckf
1 Jun 20
Prospectus supplement for primary offering
6:06am
8-K
EX-99.1
xi8dx flt
29 May 20
Regulation FD Disclosure
7:42am
8-K
EX-99.1
ht5sf55qv53ns75jp3
14 May 20
Adaptimmune Reports Q1 Financial Results
7:37am
8-K
ht30j2g
29 Apr 20
Other Events
8:06am
8-K
EX-99.1
gbjdgkmismg tqmww
29 Apr 20
Other Events
8:06am
8-K
EX-99.1
cg0x94mmw0ghd0nov
27 Feb 20
Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update
7:39am